I:SPX Oct 2023 Weekly 3100.000 - INFI STOCK NEWS

Infinity Pharmaceuticals (NASDAQ: INFI) reported its full year 2020 financial results, revealing a net loss of $40.5 million and a decrease in revenue to $1.7 million. The company highlights positive data from its clinical studies on eganelisib, particularly in combination with nivolumab for advanced urothelial cancer, showing improved overall response rate (ORR) and disease control rate (DCR) in PD-L1 low patients. With a strengthened balance sheet following a $92 million capital raise, Infinity aims to advance its clinical trials and expects to end 2021 with between $70 million to $80 million in cash reserves.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that its management will present at the Oppenheimer & Co. Annual Healthcare Conference from March 16-18, 2021. The presentation is scheduled for March 17 at 1:10 PM Eastern Time. Infinity is focused on developing eganelisib, an oral immuno-oncology therapeutic targeting immune suppression in cancer. The event can be accessed through a webcast available for 30 days post-event. For more on Infinity and eganelisib, visit www.infi.com.

Infinity Pharmaceuticals (NASDAQ: INFI) will host a conference call on March 16, 2021, at 4:30 p.m. ET, to report Q4 and full-year 2020 financial results and provide updates on its lead drug, eganelisib. This oral immuno-oncology therapy is part of ongoing clinical studies, including MARIO-275, evaluating its combination with Opdivo in urothelial cancer. The conference call can be accessed via phone or a live webcast, with an archived version available for 30 days.

Infinity Pharmaceuticals, a clinical-stage biotechnology company, announced its participation at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available for on-demand listening starting at 7:00 am ET on March 9, 2021. Infinity is developing eganelisib, an innovative immuno-oncology therapy targeted at reprogramming macrophages to combat cancer. Current clinical trials include combinations of eganelisib with well-known drugs like Opdivo, Tecentriq, and Abraxane for various cancer types. More details can be found on Infinity's website.

Infinity Pharmaceuticals (Nasdaq: INFI) has completed the sale of 24,150,000 shares at $3.80 per share, generating approximately $91.8 million in gross proceeds. The offering, which included a full over-allotment option, closed on February 17, 2021. Funds will be allocated towards the clinical development of eganelisib, a novel immuno-oncology treatment, as well as general corporate purposes. Piper Sandler & Co. served as the sole book-runner for this public offering.

Infinity Pharmaceuticals (Nasdaq: INFI) has announced the pricing of a public offering of 21 million shares of its common stock at $3.80 per share, aiming to raise approximately $79.8 million before expenses. The offering is set to close on or about February 17, 2021. The proceeds will support the clinical development of eganelisib, a novel immuno-oncology therapeutic, along with general corporate purposes. The underwriters have a 30-day option to purchase an additional 3.15 million shares.

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) has announced an underwritten public offering of its common stock, including a 30-day option for underwriters to purchase an additional 15% of shares. The offering aims to fund the clinical development of eganelisib, an immuno-oncology candidate targeting immune suppression in cancer. The registration for the offering follows SEC regulations established in April 2019. Piper Sandler & Co. is the sole book-running manager for the offering. The final terms depend on market conditions and cannot be guaranteed.

Infinity Pharmaceuticals (NASDAQ: INFI) announced its participation in the BIO CEO & Investor Conference from February 16-18. The company will present information regarding eganelisib, an innovative oral immuno-oncology therapeutic targeting immune suppression in cancer. The presentation will be available on demand starting February 16 at 10am EST. Infinity is advancing eganelisib across multiple clinical studies, addressing various cancer types through novel combination therapies. More details can be found at www.infi.com.

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) presented data from its Phase 2 study, MARIO-275, at the ASCO GU Symposium, evaluating eganelisib combined with nivolumab for advanced urothelial cancer. Results show that the combination therapy significantly benefits PD-L1 negative patients, with a 26% overall response rate compared to 14% with nivolumab alone. Additionally, 58% of PD-L1 negative patients on the combination achieved tumor burden reduction. The company plans to initiate a registration-enabling study based on these promising results.